Evidence map›Paper›PMID 37556106›Full record

ArticleInternational urology and nephrology2024

Prevalence and associated factors of frailty in patients with chronic kidney disease: a cross-sectional analysis of PEAKING study.

Changyuan Yang, Cuixia Xiao, Jiahao Zeng, Ruolan Duan, Xitao Ling, Jiamei Qiu, Qin Li, Xindong Qin, La Zhang, Jiasheng Huang and 7 more

Abstract read
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Changyuan YangThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Cuixia XiaoDepartment of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital, GuangzhouUniversity of Chinese Medicine, Guangzhou, 510000, China.
Jiahao ZengDepartment of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital, GuangzhouUniversity of Chinese Medicine, Guangzhou, 510000, China.
Ruolan DuanThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Xitao LingThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Jiamei QiuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Qin LiThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Xindong QinThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
La ZhangThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Jiasheng HuangDepartment of Nephrology, Shenzhen Hospital, Guangzhou University of Chinese Medicine, Shenzhen City, 518000, China.
Jiawei HeDepartment of Nephrology, Peking University First Hospital, Beijing City, 100034, China.
Yifan WuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Xusheng LiuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Haijing HouThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China.
Bengt LindholmDivision of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 11228, Stockholm, Sweden.
Fuhua LuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China. lufuhua@gzucm.edu.cn.
Guobin SuThe Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, 510000, China. guobin.su@gzucm.edu.cn.ORCID http://orcid.org/0000-0001-5073-9848

Funding

National Administration of Traditional Chinese medicine, P.R. China 2023ZYLCYJ02-18National Nature Science Foundation of China 82004205Research Fund for Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine BJ2022KY11the Karolinska Institutet's internal funds 2020-01616the Karolinska Institutet's internal funds 2022-02044the Science and Technology Research Fund from Guangdong provincial hospital of Chinese medicine, China YN2018QL0The Spring Sunshine Program of Scientific Research Cooperation, Ministry of Education of China HZKY20220109Traditional Chinese Medicine Bureau of Guangdong Province 20211194
6 · The paper itself

Abstract

aimFrailty is common and is reported to be associated with adverse outcomes in patients with chronic diseases in Western countries. However, the prevalence of frailty remains unclear in individuals with chronic kidney disease (CKD) in China. We examined the prevalence of frailty and factors associated with frailty in patients with CKD.

methodsThis was a cross-sectional analysis of 177 adult patients (mean age 54 ± 15 years, 52% men) with CKD from the open cohort entitled Physical Evaluation and Adverse outcomes for patients with chronic Kidney disease IN Guangdong (PEAKING). Frailty at baseline were assessed by FRAIL scale which included five items: fatigue, resistance, ambulation, illnesses, and loss of weight. Potential risk factors of frailty including age, sex, body mass index, and daily step counts recorded by ActiGraph GT3X + accelerometer were analyzed by multivariate logistic regression analysis.

resultsThe prevalence of prefrailty and frailty was 50.0% and 11.9% in patients with stages 4-5 CKD, 29.6% and 9.3% in stage 3, and 32.1% and 0 in stages 1-2. In the multivariate logistic regression analysis, an increase of 100 steps per day (OR = 0.95, 95% CI 0.91-0.99, P = 0.01) and an increase of 5 units eGFR (OR = 0.82, 95% CI 0.68-0.99, P = 0.045) were inversely associated with being frail; higher BMI was associated with a higher likelihood of being frail (OR = 1.52, 95% CI 1.11-2.06, P = 0.008) and prefrail (OR = 1.25, 95% CI 1.10-1.42, P = 0.001).

conclusionFrailty and prefrailty were common in patients with advanced CKD. A lower number of steps per day, lower eGFR, and a higher BMI were associated with frailty in this population.

Indexed as

FrailtyRenal Insufficiency, ChronicAdultAgedCross-Sectional StudiesFemaleFrail ElderlyHumansMaleMiddle AgedPrevalenceRisk FactorsAssociated factorsChronic kidney diseaseCross-sectional studyFrailtyPrevalence

Identifiers

PMID37556106
PMCPMC10808408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.